Treatment Landscape in HR+, HER2- MBC
ASCO® 2023 Insights: "Subgroup Analysis of the RIGHT Choice Trial - Outcomes With 1L Ribociclib + ET vs. Physician’s Choice Combination Chemo by Age in Pre/Perimenopausal Pts With Aggressive HR+/HER2- aBC"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Nagi El Saghir
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Nagi El Saghir
Login to view comments.
Click here to Login
Treatment Landscape in HR+, HER2- MBC